Erlotinib

A selective inhibitor of the E2 ubiquitin-conjugating enzyme Ubc13 when heterodimerized with Uev1A, blocking polyubiquitin chain formation at concentrations of 0.5 to 2 &microM in vitro blocks proliferation and induces apoptosis in DLBCL and NB

A selective inhibitor of the E2 ubiquitin-conjugating enzyme Ubc13 when heterodimerized with Uev1A, blocking polyubiquitin chain formation at concentrations of 0.5 to 2 &microM in vitro blocks proliferation and induces apoptosis in DLBCL and NB

InformationOSI-420 (DesMethyl Erlotinib, CP-473420) is the active metabolite of Erlotinib (EGFRinhibitor withIC50of 2 nM).In vitroOSI-420 is the major metabolite of Erlotinib in human plasma. Erlotinib disappearance from plasma after a short IV

A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC₅₀ = 21.5 nM) impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation.

A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC₅₀ = 21.5 nM) impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation.

A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC₅₀ = 21.5 nM) impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation.

A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC₅₀ = 0.45 nM) effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC₅₀s

A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC₅₀ = 0.45 nM) effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC₅₀s

A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC₅₀ = 0.45 nM) effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC₅₀s

Application PD168393 has been used in the acute inhibition of ErbB4. Biochem/physiol Actions PD168393 is a 6-acrylamido-4-anilinoquinazoline compound.

Application PD168393 has been used in the acute inhibition of ErbB4. Biochem/physiol Actions PD168393 is a 6-acrylamido-4-anilinoquinazoline compound.

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK: does not directly inhibit ERK1 or ERK2.A selective inhibitor of MEK and blocker of MAP.